MWNA
LAB icon

Marshall Wace North America’s Standard BioTools LAB Stock Holding History

Marshall Wace North America’s Portfolio LAB Stock Details LAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-28,913
Closed -$131K – 1626
2021
Q1 		$131K Buy
+28,913
New +$159K ﹤0.01% 1435
2020
Q3 		– Sell
-16,463
Closed -$66K – 1357
2020
Q2 		$66K Buy
+16,463
New +$57.3K ﹤0.01% 1109
2019
Q2 		– Sell
-12,003
Closed -$159K – 1380
2019
Q1 		$159K Buy
+12,003
New +$127K ﹤0.01% 1039

Other funds holding LAB

ICM
Indaba Capital Management San Francisco, California $33.8M AUM 33.83% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Neuberger Berman Group
Neuberger Berman Group New York $131B AUM 28.36% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
NIM
Needham Investment Management New York $1.96B AUM 101.23% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.71B AUM 106.31% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Marshall Wace North America's LAB Position: Q2 2021 in Review

Marshall Wace North America sold out of Standard BioTools (LAB) in Q2 2021, closing a stake of 28,913 shares — an estimated $131K sold.

Marshall Wace North America first reported a position in LAB in Q1 2019 and held it in 3 quarters. The position peaked at $159K in Q1 2019. 113 funds tracked by Wall St. Rank hold LAB as of Q2 2021.

  • Marshall Wace North America reported no remaining Standard BioTools position as of Q2 2021 after selling out during the quarter.
  • Marshall Wace North America sold 28,913 Standard BioTools shares in Q2 2021, an estimated $131K.
  • Marshall Wace North America first reported a position in Standard BioTools in Q1 2019 and held it in 3 quarters.
  • Marshall Wace North America's Standard BioTools position peaked at $159K in Q1 2019.
  • 113 funds tracked by Wall St. Rank held Standard BioTools as of Q2 2021.

Based on Marshall Wace North America's 13F filing for Q2 2021, filed 13 Aug 2021.